+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 24 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating whether adding the drug pirtobrutinib to the usual R-CHOP chemotherapy regimen improves treatment outcomes for people with Richter transformation, a condition where chronic lymphocytic leukemia or small lymphocytic lymphoma changes into a faster-growing large B-cell lymphoma. This phase III trial aims to assess safety and effectiveness of this combination compared to R-CHOP alone, with additional goals to investigate genetic mutations associated with the disease and patient-reported symptoms. Participants are randomly assigned to one of two groups. One group receives pirtobrutinib orally daily on days 1 to 21 of each 21-day cycle along with the R-CHOP drugs given intravenously or subcutaneously during 6 cycles, followed by continued pirtobrutinib for up to 5 years if the disease does not progress. The other group receives only the standard R-CHOP treatment for 6 cycles. Pirtobrutinib and R-CHOP drugs include rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone. Some patients may receive an additional treatment cycle if needed. Participants undergo various assessments including heart function tests echocardiography or MUGA scan and imaging scans CT or PETCT throughout the study. Blood and tissue samples are collected for genetic and disease monitoring. Researchers measure progression-free survival, overall survival, response rates, adverse events, and patient-reported symptoms. Follow-up continues for up to 7 years after treatment to monitor long-term outcomes and safety.

Age: 18Years +All GendersPhase 3
62 locations
C

Actively Recruiting

Researchers are evaluating treatments for patients with advanced head and neck cancer that has spread locally or to distant parts and who cannot receive cisplatin. This phase III trial compares two approaches combined with intensity modulated radiation therapy IMRT cetuximab, a monoclonal antibody targeting EGFR on cancer cells, versus chemotherapy with carboplatin and paclitaxel. The study aims to determine which treatment better controls the cancer and improves survival while considering safety and quality of life. Participants are randomly assigned to one of two groups. One group receives IMRT five days per week for 35 treatments alongside cetuximab given intravenously as a loading dose before radiation and then weekly concurrent infusions for seven cycles. The other group receives the same IMRT schedule with weekly intravenous carboplatin and paclitaxel for seven cycles during radiation. Both groups undergo imaging scans like CT, MRI, or PETCT during screening and follow-up, as well as blood sample collections throughout the study. Participants are followed after treatment completion at 30 days, then at 4, 6, 12, 18, 24, 30, and 36 months, and annually thereafter. Researchers collect data on cancer progression, survival, treatment side effects, and changes in diet, eating, and speech. The main outcome measured is progression-free survival up to eight years, with additional monitoring of overall survival, adverse events, patterns of cancer recurrence, and quality of life changes over time.

Age: 18Years +All GendersPhase 3
150 locations
R

Actively Recruiting

Researchers are comparing two treatments, rituximab and mosunetuzumab, for patients with follicular lymphoma that has a low tumor burden. This phase III trial aims to see which treatment better helps patients avoid disease progression or worsening over time. Both drugs are monoclonal antibodies targeting cancer cells, but it is unknown which one is more effective for this condition. Participants are randomly assigned to one of two groups. One group receives rituximab intravenously on day 1 of the first cycle, then rituximab with hyaluronidase subcutaneously on days 8, 15, and 22 of the first cycle and on day 1 of later cycles cycles repeat every 56 days for up to 5 cycles. The other group receives mosunetuzumab subcutaneously on days 1, 8, and 15 of the first cycle and day 1 of later cycles cycles repeat every 21 days for up to 8 cycles. During treatment, participants have CT or PETCT scans and blood samples collected. After treatment, participants are followed every 6 months for 5 years and then yearly up to 10 years. Researchers assess progression-free survival, overall survival, response rates, event-free survival, and treatment side effects. Specimens are also collected for future research. The total participation may last up to 10 years, including long-term monitoring for disease status and safety.

Age: 18Years +All GendersPhase 3
288 locations
R

Actively Recruiting

Researchers are evaluating how well sentinel lymph node SLN biopsy surgery works compared to standard elective neck dissection END for treating early-stage oral cavity squamous cell carcinoma cT1-2N0. This phase IIIII trial aims to see if SLN biopsy leads to better patient-reported neck and shoulder function and quality of life six months after surgery, while also assessing if disease-free survival with SLN biopsy is not worse than with END. The study also examines patterns of cancer recurrence, overall survival, and treatment toxicity between the two surgical approaches. Participants are randomly assigned to one of two groups. In Group I, patients receive an imaging agent injection followed by planar imaging and SPECTCT scans over 1-2 hours, then undergo SLN biopsy surgery. Group II patients undergo the standard elective neck dissection surgery. Both groups have imaging assessments including FDG PETCT, CT, andor chest x-rays at screening and during follow-up. The trial also collects patient-reported outcomes using questionnaires and measures surgical factors like hospital stay length and operative morbidity. During the study, participants complete quality of life and function questionnaires before surgery, and at 3 weeks, 3, 6, and 12 months after surgery. Follow-up visits occur 3 weeks post-surgery, every 3 months for the first year, every 4 months in the second year, every 6 months in the third year, and yearly thereafter. Researchers monitor disease-free survival, overall survival, and other outcomes for up to 11 years. Biospecimens are also collected for future studies.

Age: 18Years +All GendersPhase 2Phase 3
107 locations
R

Actively Recruiting

Researchers are evaluating the treatment of older adults aged 75 and above with early-stage cutaneous melanoma. The study compares the effectiveness of wide local excision WLE alone to the usual care of WLE combined with sentinel lymph node SLN biopsy. The main goal is to see if the less invasive WLE alone can provide similar results in preventing melanoma recurrence. This phase III trial also aims to assess patient-reported outcomes and the impact of geriatric assessments on treatment results. Participants are randomly assigned to one of two groups one group receives WLE plus SLN biopsy, and the other group receives WLE alone. Both groups may undergo surveillance of the lymph node area and receive additional treatments called adjuvant therapies if needed. Throughout the study, participants may have imaging tests such as computed tomography CT, positron emission tomography PETCT, or ultrasound. After initial treatment, patients are monitored closely with regular follow-ups. During the study, participants will be followed every four months for two years and then every six months up to five years after randomization. Researchers will collect data on recurrence-free survival, overall survival, melanoma-specific survival, safety, and patient quality of life. The study also involves comprehensive geriatric assessments and questionnaires to evaluate physical and functional status. These measures will help develop tools to predict risks and guide future surgical decisions for older adults with melanoma.

Age: 75Years +All GendersPhase 3
181 locations
S

Actively Recruiting

This trial focuses on patients with CD22-positive B-lineage acute lymphoblastic leukemia ALL that is newly diagnosed, has returned after improvement, or does not respond to treatment. Researchers are studying how well the combination of inotuzumab ozogamicin and blinatumomab, with or without ponatinib, works in treating this type of leukemia. The study aims to confirm tolerability and estimate survival and response rates in different patient groups, including those with Philadelphia chromosome-negative and positive disease. Participants are assigned to one of three groups. Cohorts 1 and 2 receive inotuzumab ozogamicin intravenously on specific days, followed by blinatumomab infusions over several weeks. Cohort 3 receives a combination of ponatinib pills daily, intravenous inotuzumab ozogamicin, blinatumomab infusions, dexamethasone, methotrexate injections into the spine, and may receive allogeneic hematopoietic cell transplantation based on response. Treatment courses vary in length from 21 days to 126 days, followed by a maintenance phase with ponatinib lasting up to 24 months. Throughout the study, participants undergo bone marrow aspiration and biopsy, blood and cerebrospinal fluid sample collection, and lumbar punctures. Researchers monitor event-free survival, overall survival, relapse-free survival, response rates, molecular responses, and treatment safety for up to 10 years. After completing treatment, patients have follow-up visits every 3 months for 3 years, then every 6 months for up to 10 years to assess long-term outcomes and side effects.

Age: 18Years +All GendersPhase 2
285 locations
M

Actively Recruiting

Researchers are evaluating a Master Screening and Reassessment Protocol MSRP to improve the matching of patients with myeloid cancers, such as acute myeloid leukemia AML or myelodysplastic syndrome MDS, to appropriate clinical trials or standard treatments. This study focuses on using bone marrow and blood tests to detect biomarkers that guide treatment decisions, aiming to assign participants quickly to targeted treatment studies or standard care pathways. The study also assesses the ability to organize and process data rapidly to support treatment assignments. Participants undergo bone marrow aspiration and blood collection for rapid genetic testing to identify mutations that may be targeted by specific therapies within various substudies. If no targetable mutation is found, participants may be assigned to novel combination drug studies or continue standard of care through the Tier Advancement Pathway TAP. Treatments studied include various drug regimens involving agents such as azacitidine, venetoclax, cytarabine, daunorubicin, and others, administered intravenously, subcutaneously, or orally according to specific schedules. Some participants may also receive hematopoietic stem cell transplantation with conditioning regimens. Treatment cycles vary in length and number depending on the assigned substudy. Throughout the study, participants have multiple bone marrow aspirations, biopsies, blood sample collections, and imaging tests such as echocardiography or MUGA scans for monitoring. Researchers assess timing for treatment assignment, response rates, adverse events, and overall survival among other outcomes. The study includes ongoing reassessment to allow movement to higher tier treatment options when appropriate. Participation may last for extended periods, with some regimens continuing up to two years or more, depending on response and disease progression.

Age: 18Years +All GendersPhase 2
360 locations
S

Actively Recruiting

Researchers are evaluating whether 6 months of HER2-targeted therapy is as effective as 12 months for treating early-stage HER2-positive breast cancer in patients who have no remaining invasive cancer after preoperative chemotherapy with trastuzumab. The study aims to compare recurrence-free survival and quality of life between shorter and longer treatment durations. Secondary goals include assessing serious side effects, overall survival, local cancer recurrence, and patient-reported symptoms. Participants are randomly assigned to either 6 months or 12 months of HER2-targeted therapy using trastuzumab and possibly pertuzumab, given intravenously or subcutaneously every 21 days. Treatment continues up to 9 or 17 cycles unless disease progresses or side effects are unacceptable. During the trial, participants undergo heart function tests ECHO or MUGA, imaging such as mammography, ultrasound, or MRI, and may provide blood and tissue samples for research. After treatment, participants are followed every 6 months for 5 years or until cancer recurrence, then annually up to 10 years. Researchers monitor recurrence-free survival and quality of life using validated questionnaires. Safety is closely tracked through adverse event reporting, and long-term outcomes including overall survival and brain metastasis occurrence are assessed to understand treatment impact.

Age: 18Years +All GendersPhase 3
702 locations
N

Actively Recruiting

Researchers are investigating whether adding preoperative chemotherapy to surgery improves the outcomes for patients with high risk retroperitoneal sarcoma, specifically dedifferentiated liposarcoma DDLPS and leiomyosarcoma LMS. This phase III randomized trial compares the effects of surgery alone versus surgery following chemotherapy on disease-free survival in these patients. Participants are assigned to one of two groups the standard treatment group, which undergoes large en-bloc curative-intent surgery within four weeks after randomization, or the experimental group, which receives three cycles of chemotherapy before surgery. Chemotherapy regimens differ by sarcoma type, with high grade LPS patients receiving doxorubicin plus ifosfamide every three weeks, and LMS patients receiving doxorubicin plus dacarbazine every three weeks. Surgery is then scheduled 3 to 6 weeks after the last chemotherapy cycle, with doses adapted per institutional guidelines. During the study, participants undergo imaging assessments to evaluate tumor operability and response to treatment. Researchers monitor disease-free survival over seven years from the first patient enrolled, along with secondary outcomes including overall survival, recurrence, metastasis rates, treatment safety, quality of life, and pathological response. Participants are closely followed through scheduled visits and tests to assess treatment effects and potential complications until study completion in 2028.

Age: 18Years +All GendersPhase 3
176 locations
C

Actively Recruiting

Researchers are studying newly diagnosed patients with IDH wildtype, MGMT-unmethylated glioblastoma to compare two types of radiation therapy combined with temozolomide chemotherapy. This phase III trial focuses on whether temporally-modulated pulsed radiation therapy TMPRT alongside temozolomide can better preserve memory and thinking functions and improve survival compared to standard radiation therapy with temozolomide. The study also addresses the challenges of treating MGMT-unmethylated tumors, which often respond less to chemotherapy alone. Participants are randomly assigned to one of two groups. The first group receives standard radiation therapy daily over 12-15 minutes for 3 or 6 weeks, along with daily oral temozolomide for 21 or 42 days, followed by additional temozolomide cycles every 28 days for six cycles. The second group receives TMPRT delivered in 10-13 pulses with 3-minute breaks over 30-40 minutes each session, also 5 days a week for 3 or 6 weeks, combined with the same temozolomide schedule as the first group. After radiation, both groups continue temozolomide in cycles. Throughout the trial, participants undergo CT or MRI scans and may provide optional blood samples. During the study, participants complete neurocognitive testing to track memory and thinking abilities, quality of life questionnaires, and assessments of frailty. Researchers monitor overall survival, progression-free survival, and adverse events up to 9 months after radiation therapy. Follow-up visits occur at months 1, 3, 5, 7, 9, and 12, then annually for 4 years. Blood samples are collected for future research, and imaging is used to evaluate brain changes. The trial lasts several years, with careful monitoring to evaluate the impact of the different radiation therapies combined with temozolomide.

Age: 18Years +All GendersPhase 3
54 locations

1-10 of 24

1